Sleeve Gastrectomy after Renal Transplantation

Area of Science:

• Nephrology
• Bariatric Surgery
• Transplantation Medicine

Background:

• Obesity is a significant risk factor for developing and worsening diabetes (DBT), hypertension (HT), and dyslipidemia (DSL), major contributors to renal failure.
• Obesity negatively impacts patients post-renal transplantation (RT), increasing mortality, complications, and graft loss.
• The potential benefits of bariatric surgery in obese RT patients remain an area of investigation.

Purpose of the Study:

• To evaluate the effects of sleeve gastrectomy (SG) on obese patients with a history of renal transplantation (RT).
• To assess improvements in comorbidities, kidney function, graft survival, and quality of life following SG in this patient cohort.

Main Methods:

• Retrospective review of prospectively collected data from patients who underwent sleeve gastrectomy (SG) after renal transplantation (RT).
• Assessment of demographics, anthropometric data, comorbidities, postoperative course, immunosuppression, transplantation details, kidney function, graft survival, and quality of life via survey.
• Analysis of data from five kidney transplant patients between January 1, 2012, and January 1, 2016.

Main Results:

• Patients (80% female) had a mean preoperative BMI of 42.18 kg/m², with 100% having HT and DSL, and 40% having DBT.
• Post-SG, mean follow-up was 16.8 months, with a significant reduction in BMI to 29.8 kg/m².
• Improvements were observed in blood pressure, laboratory values for HT and DSL, and diabetes management (insulin reduction/discontinuation). 80% showed improved graft function and proteinuria. Quality of life significantly improved for all patients.

Conclusions:

• Sleeve gastrectomy (SG) demonstrates encouraging outcomes in high-risk obese patients with a history of renal transplantation (RT).
• The procedure led to significant weight loss, improvement or resolution of comorbidities (HT, DSL, DBT), enhanced renal function, and better quality of life.
• SG represents a potentially beneficial intervention for managing obesity in post-renal transplant recipients.